Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,412.02
(
-1.01%
)
US TECH 100
22,670.40
(
-1.23%
)
Dow Jones
45,478.23
(
-1.05%
)
Brent Oil
104.86
(
4.16%
)
Bitcoin
66,156.99
(
-3.82%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biocqr post# 169304

Monday, 11/04/2013 7:33:14 PM

Monday, November 04, 2013 7:33:14 PM

Post# of 257295
ABBV/ENTA—One thing the EP Vantage article didn’t mention: In addition to the six phase-3 trials to be submitted with the initial NDA in 2Q14, there are three ancillary phase-3 trials—one for HIHCV/HIV co-infection and two going head-to-head with Incivekr + peg/riba; these are the three trials shown at the bottom of #msg-93647264.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today